Project Grant R01DE034803
- The National Institute of Dental and Craniofacial Research awarded a cooperative agreement to The Regents of the University of California, San Francisco for $525,127 on September 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121). The award funds XERO STUDY, a Phase I clinical investigation of CVGN8, an injectable neuromimetic hydrogel therapeutic designed to restore salivary gland function in patients with radiation-induced xerostomia. CVGN8 encapsulates cevimeline,...
- The National Institute of Dental and Craniofacial Research awarded The Research Foundation for the State University of New York $440,275 on February 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate transcriptional regulatory mechanisms of salivary gland regeneration in a defined genetic model. The award funds research examining how the master transcription factor SIX1 governs stem and progenitor cell activity, cell fate determination, and...
- The National Institute of Dental and Craniofacial Research awarded Icahn School of Medicine at Mount Sinai $150,590 on December 1, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support research defining the role of tissue-resident macrophages (TRMs) during salivary gland morphogenesis. The research addresses salivary gland dysfunction caused by conditions such as Sjögren's syndrome and head and neck cancer irradiation, which lead to hyposalivation and...
- The National Institute of Dental and Craniofacial Research awarded the University of Missouri System $304,650 on July 6, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to engineer cell sheets that restore salivary gland function in irradiated mice. The research addresses permanent salivary gland damage caused by radiation therapy for head and neck cancer, for which current treatments—saliva substitutes and secretory agonists—remain largely ineffective. The project...
- The National Institute of Dental and Craniofacial Research awarded The Regents of the University of California, San Francisco $451,000 on August 6, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the mechanisms of intrafibrillar mineralization of collagen fibrils through the polymer-induced liquid precursor (PILP) pathway. The research examines how calcium and phosphate ions are captured and delivered to collagen mineralization sites, and explores the...
- The National Institute of Dental and Craniofacial Research awarded University of Massachusetts Lowell $445,389 on August 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate SATB2 as a mandible-specific mediator of GLI3 transcription in craniofacial development. The research examines how specific transcription factor co-factors regulate GLI3 activity in the developing mandible without requiring a sonic hedgehog morphogen gradient, contrasting with...
- The National Institute of Dental and Craniofacial Research awarded The Regents of the University of California, San Francisco $328,000 on August 28, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop and validate an electronic health record–based phenotype of xerostomia and build a preliminary AI-driven risk prediction model for oral health complications. The project develops natural language processing methods to extract xerostomia cases and social risk...
- The National Institute of Dental and Craniofacial Research awarded Northern California Institute For Research And Education, Inc. $499,022 on August 15, 2026, to conduct research elucidating the role of GS-GPCR signaling at the bone-vascular interface under the Oral Diseases and Disorders Research program (CFDA 93.121). The project investigates molecular mechanisms by which GS-GPCR signaling in endothelial and perivascular cells contributes to osteogenesis and fibrosis, using fibrous dysplasia...
- The National Institute of Dental and Craniofacial Research awarded $1.368593 million to The Regents of the University of California, San Francisco on July 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate aberrant mechano-oxygen coupling as a driver of zinc-enriched ectopic mineralization in osteoarthritis. The research integrates complementary expertise across three principal investigators. Longitudinal studies in rats with overloaded...
- The National Institute of Dental and Craniofacial Research awarded the University of Rochester $415,813 on July 7, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop a modular microphysiologic system (MPS) for culturing three-dimensional innervated salivary gland tissue mimetics in array format. The funded research will create a platform capable of static and optional perfused culture of organoids and tissues arranged in arrays, addressing a gap in current...
The National Institute of Dental and Craniofacial Research awarded The Regents of the University of California, San Francisco $696,710 on August 10, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the role of the genome organizer protein SATB1 in salivary gland maturation and regeneration. The research addresses the absence of viable long-term treatments for salivary gland dysfunction resulting from disease or chronic injury, particularly xerostomia induced by therapeutic ionizing radiation in head and neck cancer treatment affecting approximately 50,000 cases annually. The project examines how SATB1 establishes three-dimensional chromatin architecture and regulates cell-type-specific gene expression during postnatal submandibular gland maturation, with the goal of understanding mechanisms that control salivary gland generation from stem cells and regeneration following radiation-induced damage. Preliminary studies indicate SATB1 plays a critical role in establishing acinar cells and cellular architecture, positioning it as a potential regulator of lineage specification for therapeutic applications. Work is performed in San Francisco, California, with a period of performance extending from August 10, 2026, through May 31, 2031. This is a Project Grant, a standard assistance vehicle for hypothesis-driven biomedical research under NIDCR's extramural research mission to advance fundamental knowledge in dental, oral, and craniofacial health and translate findings into prevention and treatment strategies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $696.7k | 8/10/26 |